Short answer: US search interest in research peptides rose steeply through the GLP-1 era, led by retatrutide, tirzepatide and semaglutide, with several terms flagged as Google Trends Breakout queries in the United States. The 2023–25 FDA compounding shake-up then nudged search toward research-compound, supplier and Certificate-of-Analysis terms - a more research-literate audience. As always: this report tracks search interest, not clinical demand, sales, FDA approval or any endorsement of human use. New-U supplies every compound strictly for laboratory research; the US range is at Buy Peptides in the USA.
No country produced more peptide-related search volume over the last three years than the United States, and no category drove it like the GLP-1 incretins. On Google Trends for the US, the umbrella term “peptides” rose steadily while the specific incretin compounds - semaglutide, tirzepatide and especially retatrutide - went vertical. This report breaks down what is rising, why the FDA backdrop matters, and what the data does and does not mean.
How to read these figures. Google Trends reports relative interest on a 0–100 scale, and its “Breakout” label just means a query grew more than +5,000% off a low base. We avoid quoting a single headline percentage because it shifts with the window and the query. The trustworthy signal is the direction - and across US research-peptide search, the direction is up.
| Compound | US search-interest arc | Mechanism / class | US regulatory status |
|---|---|---|---|
| Retatrutide (“reta”) | Breakout since 2023 | Triple GLP-1 / GIP / glucagon agonist | Not approved - Phase 3, research only |
| Tirzepatide (“tirz”) | Steep 2023–24 climb | Dual GLP-1 / GIP agonist | FDA-approved (Mounjaro / Zepbound) |
| Semaglutide (“sema”) | Sustained high since 2022 | GLP-1 agonist | FDA-approved (Ozempic / Wegovy) |
| BPC-157 / TB-500 | Broad, durable interest | Tissue-repair research peptides | Not approved - research only |
The standout is retatrutide - the “reta” surge is sharp enough to warrant its own breakdown in Why “Reta” Searches Are Surging in the USA. The dual-agonist story has its own arc too, covered in Tirzepatide Search Demand in the USA.
The American trend has a regulatory texture the rest of the world doesn’t. During the 2022–24 branded-GLP-1 shortages, compounding pharmacies were permitted to prepare certain GLP-1 products, and US search filled with compounding and sourcing queries. As shortages resolved and the FDA tightened that window, search interest didn’t fall - it shifted, toward research-compound terms, supplier-vetting queries and “Certificate of Analysis” searches. We track that regulatory thread in FDA GLP-1 Compounding & 503B in 2026 and the broader picture in Peptides & the FDA.
Plain-English summary. Most of the fastest-rising US peptide search terms are for unapproved compounds. In the US they are supplied as research chemicals for laboratory use - labelled research use only, no human-use claims. New-U publishes no US dosing or protocols and makes no therapeutic claims for any compound. For anything health-related, consult a licensed clinician.
Because the top-trending compounds are unapproved, US researchers source them from research-compound suppliers, not pharmacies. The supplier bar is documentation: research-use-only labelling, no health claims, a per-batch Certificate of Analysis with HPLC purity (>99% is the credible standard) and mass-spec identity from a named third-party lab, and a verifiable legal entity. Our walkthrough is how to buy research peptides.
On the New-U catalogue, US researchers most often begin with Retatrutide, Tirzepatide and Semaglutide, each with a dedicated US page covering FDA framing, USD pricing and tracked delivery to New York, Los Angeles, Chicago, Houston, Miami, Seattle and across the country. Shipping is $25 flat, free over $300. The full US range is at Buy Peptides in the USA; the commercial overview for the breakout compound is /peptide/retatrutide.
The American surge is the largest by volume, but the shape repeats abroad - GLP-1-led search growth within each country’s own regulatory framing. Read it alongside the UK (MHRA) and Australian (TGA) reports to see how universal the GLP-1 search wave has become.
Is demand for peptides rising in the USA?
US search interest in research peptides climbed steeply through the GLP-1 era, with retatrutide, tirzepatide and semaglutide leading and several Breakout terms. This tracks search curiosity, not clinical demand, sales or any endorsement of human use.
How did the FDA compounding changes affect search?
As branded GLP-1 supply normalised and compounding rules tightened, US search shifted toward research-compound, supplier and Certificate-of-Analysis terms - a more research-literate audience.
Are research peptides legal to buy in the USA?
Research compounds can be bought for laboratory use when labelled research use only with no human-use claims. Many are not FDA-approved drugs and cannot be sold or used as medicines. New-U supplies them strictly for research use.
Does rising search interest mean a peptide is FDA-approved or safe?
No. Search popularity is unrelated to FDA approval, safety or efficacy. Several of the most-searched compounds are investigational. New-U makes no human-use claims for any compound.
Search-interest figures are directional and depend on the query and date range chosen in Google Trends; New-U is not affiliated with Google or these organisations and links carry no endorsement. Nothing here is medical advice.
New-U Research Compounds ships the full research range to US addresses in sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a per-batch Certificate of Analysis. Tracked US delivery, free over $300. Research use only - not for human consumption.
Browse the USA catalogue